Efficacy of Bee Venom Phonophoresis in Treatment of Plaque Psoriasis

Efficacy of bee venom phonophoresis in treatment of plaque psoriasis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR202101485247187

Enrollment

Registered

2021-01-19

Start date

2021-01-16

Completion date

Unknown

Last updated

2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Skin and Connective Tissue Diseases

Interventions

Study group A

Study group B

Control group C

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: -Patients' ages ranged from 20 to 50 years -They had moderate-grade plaque psoriasis in the upper and lower extremities -Disease duration ranged from 6 to 18 months

Exclusion criteria

Exclusion criteria: Patients with diabetes, peripheral vascular diseases, acute viral diseases or a history of allergic skin, and dermatitis. - Pregnant patients and patients with contraindications to ultrasound

Design outcomes

Primary

Measure	Time frame
The Psoriasis Area Severity Index (PASI) was used to measure the severity of psoriasis (the largest patch of psoriasis or area with adjacent small patches in each region) as psoriasis locations were divided into the upper (U) and lower (L) extremities, the symptom score was calculated as the erythema (Er), infiltration (In), and desquamation (De) grades were determined on a scale as none for (zero), slight for (one), moderate for (two), severe for (three) and severe for (four) and the percentage score of each area (A) involved was calculated on a scale as follows; the score (0) for 0%, (1) for (1% - 9%), (2) for (10% - 29%),(3) for (30% - 49%), (4) for (50% - 69%), (5) for (70% - 89%), and score (6) for (90% - 100%). Taking into consideration that the area of upper limbs represents (0.2 ) of body surface area, while the area of lower limbs represents (0.4) of body surface area. Then, the following PASI formula was used to estimate total scores in the study The Psoriasis Area Severity Index scores = (0.2 (DeU+ErU+InU) AU + 0.4 (DeL+ErL+InL) AL)	—

Measure

Time frame

The Psoriasis Area Severity Index (PASI) was used to measure the severity of psoriasis (the largest patch of psoriasis or area with adjacent small patches in each region) as psoriasis locations were divided into the upper (U) and lower (L) extremities, the symptom score was calculated as the erythema (Er), infiltration (In), and desquamation (De) grades were determined on a scale as none for (zero), slight for (one), moderate for (two), severe for (three) and severe for (four) and the percentage score of each area (A) involved was calculated on a scale as follows; the score (0) for 0%, (1) for (1% - 9%), (2) for (10% - 29%),(3) for (30% - 49%), (4) for (50% - 69%), (5) for (70% - 89%), and score (6) for (90% - 100%). Taking into consideration that the area of upper limbs represents (0.2 ) of body surface area, while the area of lower limbs represents (0.4) of body surface area. Then, the following PASI formula was used to estimate total scores in the study The Psoriasis Area Severity Index scores = (0.2 (DeU+ErU+InU) AU + 0.4 (DeL+ErL+InL) AL)

—

Secondary

Measure	Time frame
Ultrasonography with high resolution (40-MHz) was used to evaluate the skin thickness of the target area concerning a fixed point in the affected area, which was determined in relation to a landmark (acromion as a landmark for the arm, olecranon for the forearm, the greater trochanter for the thigh, and the patella was a landmark for the leg).	—

Countries

Egypt

Contacts

Public ContactHesham Mahran

Assistant Professor

heshammahran75@yahoo.com+201030792492

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Feb 4, 2026